根据SEC申报文件显示,Clearside Biomedical Inc的出售方就SCS微注射器资产获得了额外300万美元的收入。
根据SEC申报文件显示,Clearside Biomedical Inc的出售方就SCS微注射器资产获得了额外300万美元的收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.